The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Hdl Handle:
http://hdl.handle.net/10144/619139
Title:
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Authors:
Reuter, A; Tisile, P; von Delft, D; Cox, H; Cox, V; Ditiu, L; Garcia-Prats, A; Koenig, S; Lessem, E; Nathavitharana, R; Seddon, JA; Stillo, J; von Delft, A; Furin, J
Journal:
The International Journal of Tuberculosis and Lung Disease
Abstract:
For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.
Publisher:
International Union Against Tuberculosis and Lung Disease
Issue Date:
1-Nov-2017
URI:
http://hdl.handle.net/10144/619139
DOI:
10.5588/ijtld.17.0468
PubMed ID:
29037291
Submitted date:
2018-05-16
Language:
en
ISSN:
1815-7920
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorReuter, Aen
dc.contributor.authorTisile, Pen
dc.contributor.authorvon Delft, Den
dc.contributor.authorCox, Hen
dc.contributor.authorCox, Ven
dc.contributor.authorDitiu, Len
dc.contributor.authorGarcia-Prats, Aen
dc.contributor.authorKoenig, Sen
dc.contributor.authorLessem, Een
dc.contributor.authorNathavitharana, Ren
dc.contributor.authorSeddon, JAen
dc.contributor.authorStillo, Jen
dc.contributor.authorvon Delft, Aen
dc.contributor.authorFurin, Jen
dc.date.accessioned2018-05-17T14:27:56Z-
dc.date.available2018-05-17T14:27:56Z-
dc.date.issued2017-11-01-
dc.date.submitted2018-05-16-
dc.identifier.citationThe devil we know: is the use of injectable agents for the treatment of MDR-TB justified? 2017, 21 (11):1114-1126 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920-
dc.identifier.pmid29037291-
dc.identifier.doi10.5588/ijtld.17.0468-
dc.identifier.urihttp://hdl.handle.net/10144/619139-
dc.description.abstractFor decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.en
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.rightsArchived with thanks to The International Journal of Tuberculosis and Lung Diseaseen
dc.titleThe devil we know: is the use of injectable agents for the treatment of MDR-TB justified?en
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.